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Acetylcholine receptor (AChR) gene expression was analyzed in experimental autoimmune myasthenia gravis (EAMG) in rabbits, rats and mice. 
An increase in AChR transcripts was demonstrated to be exclusively associated with myasthenic symptoms and with a severe loss in membrane 
AChR. An increase of a-, /I-, E-, and &subunit specific mRNAs (5.2-, 1.6-, 3.2- and 3.7-fold, respectively), which code for the adult type of AChR 
(o+/?ss) was observed in EAMG in rats. The y-subunit ranscript was not detectable in myasthenic or healthy rats. It appears that the regulatory 
control of AChR gene expression in EAMG is different from that observed upon denervation. 
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1. INTRODUCTION 
The nicotinic acetylcholine receptor (AChR) is an 
oligomeric complex of four types of subunits present in 
a molar stoichiometry of LY$~~c? [ 1,2]. A fifth subunit 
called e-subunit was first discovered in calf muscle [3] 
and was later shown also to exist in rat [4] and mouse 
muscle [5]. The AChR polypeptides are under 
developmental control which leads in mammals to the 
expression of two types of channels [6,7]. At early 
developmental stages a low conductance channel com- 
prised of u-, fl-, y- and d-subunits predominates. The 
channels of the adult muscle have a higher conductance 
and contain mainly LY-, P-, e- and S-subunits [6]. Upon 
denervation of adult muscle a large increase in AChR 
is observed and the majority of these newly synthesized 
receptors represents low conductance channels con- 
sisting of (Y-, ,&, y- and a-subunits [4]. The correlation 
of functional changes, with changes in the content of y- 
and e-subunit specific mRNAs, supports the view that 
the exchange of a single subunit is responsible for the 
channel conversion observed during development or 
upon denervation [4,6,7]. AChR is the major autoan- 
tigen in myasthenia gravis (MG) and its animal model 
experimental autoimmune myasthenia gravis (EAMG). 
Immune attack of AChR at the neuromuscular junc- 
tion leads to a decrease in the receptor content and im- 
pairs signal transmission from nerve to muscle [8]. 
muscles of myasthenic rabbits and rats 191. In the pres- 
ent study we demonstrate that in addition to the in- 
crease in the .&subunit mRNA, there is also an 
elevation in the mRNA for the &, f- and b-subunit in 
myasthenia rats. This type of increase corresponds to 
an adult class of receptors. We also demonstrate in this 
report that the increase in AChR mRNA levels cor- 
relates exclusively with disease. 
2. MATERIALS AND METHODS 
2.1. AChR preparations 
AChR was purified from Torpedo californica electric organ 
(Pacific Bio-Marine, Venice, CA) as described (10). Reduced and car- 
boxymethylated AChR (RCM-AChR) was prepared as previously 
described Ill]. Muscle AChR preparations from the hind legs of rab- 
bits and rats were made essentially as described previously [12] and 
AChR content was determined by measuring binding of [‘z51]a- 
bungarotoxin ((u-BTX) [lo]. 
2.2. Immunological procedures 
In a previous report we demonstrated that there are 
increased levels of AChR a-subunit mRNA in leg 
Immunization of rabbits and rats and induction of EAMG were 
performed as previously described [9]. Female C57BL/6, SJL/J and 
SWR mice (10 weeks old) were injected in their footpads with 
purified AChR (10 cg per mouse) emulsified with complete Freund’s 
adjuvant (CFA). Mice were boosted twice or three times at monthly 
intervals with 10 pg AChR until myasthenic symptoms were detected. 
Myasthenic symptoms in mice and rats included motor impairment, 
ruffled fur, exaggeratedly humped backs, weight loss and fatigability, 
which was accentuated by exercise. For all species, animals in- 
jected with CFA alone were used as controls. Rabbit, mouse and rat 
sera were tested for antibody titers by solid-phase radioimmunoassay 
using purified Torpedo AChR as the antigen and ‘2sI-labeled protein 
A for the detection of antibody binding [13]. 
2.3. Northern blot analysis 
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immediately after dissection, for determination of AChR content and 
for preparation of RNA. PoIy(A)+ RNA preparations and Northern 
blot analysis were performed as described previously [9]. The AChR- 
specific hybridization probes employed for the (Y-, ,& and &subunits 
were 2 kb EcoRI fragments derived from the respective mouse 
recombinant DNAs [14-161, and were kindly provided by Dr S. 
Heinemann. The y- and f-probes were genomic rat fragments as 
described in [4]. An cY-actin specific probe was a gift from Dr U. 
Nudel. 
A. 
3. RESULTS B. 
In our previous [9] report we demonstrated that 
AChR a-subunit mRNA increases in myasthenic 
animals. In order to find out whether this increase is 
directly connected to EAMG, or whether it is merely a 
result of an immune response to AChR, we have 
analyzed AChR gene expression in rabbits immunized 
with AChR or with a denatured preparation of AChR 
(reduced and carboxymethylated AChR, RCM-AChR 
[ 111). As previously reported [l 11, RCM-AChR- 
injected rabbits developed anti-AChR antibody titers 
(Fig. IA) but did not exhibit myasthenic symptoms. 
When EAMG was observed in the AChR-injected rab- 
bits, animals from both groups as well as from a con- 
trol group of animals immunized with CFA, were 
sacrified and poly(A)+ RNA was prepared from hind 
leg muscles. Northern blot analysis of the poly(A)+ 
RNA preparations (Fig. 2) shows an increase (3.75 + 
0.35fold, calculated on the basis of densitometric 
analysis of three different rabbits) in the level of the a- 
subunit mRNA in AChR-injected, myasthenic rabbits, 
whereas all rabbits immunized with RCM-AChR did 
not exhibit any significant increase. It should be noted 
that in earlier preliminary experiments [9] it seemed 
that an RCM-AChR-injected rabbit exhibited some in- 
crease in AChR transcripts, but this observation was 
not reproduced. The levels of a-actin mRNA were vir- 
tually identical in all animals (Fig. 2), reflecting the 
selective increase in AChR a-subunit mRNA in 
myasthenic rabbits. 
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Fig. 2. AChR o-subunit transcripts in rabbits. 10 pg each of poly(A)+ 
RNA isolated from leg muscle of rabbits injected with CFA (lane 1) 
RCM-AChR (lanes 2, 3) and AChR (myasthenic) (lanes 4, 5) were 
size-fractionated on denaturing agarose gel and transferred to Gene 
Screen plus membrane filters. The blot was then hybridized with an 
o-subunit cDNA probe from mouse (A) and following stripping, with 
an cu-actin probe (B). 
The increase in AChR mRNA levels in myasthenic 
AChR-injected rabbits was accompanied by 46% 
decrease in the content of membranal AChR, as com- 
pared to its content in control CFA-injected rabbits 
(31.1 + 2.4 and 16.7 +- 3.3 fmol cu-bungarotoxin (a- 
BTX) per mg protein in control and myasthenic rab- 
bits, respectively). Some decrease (about 21%) in the 
surface AChR content was also observed in RCM- 
AChR-injected, disease-free, rabbits (24.6 f 4.3 fmol 
a-BTX/mg protein). 
In mice we have analyzed the level of AChR a- 
subunit mRNA in EAMG susceptible and non- 
Serum dilutlon 
Fig. 1. Anti-AChR antibody titers in rabbits (A), mice (B) and rats (C), as determined by solid phase radioimmunoassay. (A) AChR-injected, 
myasthenic rabbit (0); RCM-AChR-injected rabbit (A); control, CFA-injected rabbit (0). (B) Myasthenic (0) and nonmyasthenic (A) AChR- 
injected, and CFA-injected (a) C57BL/6 mice; AChR-injected (0) and CFA-injected (m) SWR mice. (C) Myasthenic (0) and nonmyasthenic (A) 
AChR-injected rats and CFA-injected (0) rat. 
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Fig. 3. Northern blot analysis of AChR cu-subunit ranscripts in 
mouse muscles, hybridized with AChR a-subunit probe (A) and (Y- 
actin probe (B). Poly(A)+ RNA (10 peg) from CFA-injected C57BL/6 
(lane l), AChR-injected (nonmyasthenic) CS7BL/6 (lane 2), AChR- 
injected myasthenic C57BL/6 (lane 3), CFA-injected SWR (lane 4) 
and AChR-injected (nonmyasthenic) SWR mice (lane 5) were 
subjected to blot hybridization as described in Fig. 2. 
susceptible strains [ 171. EAMG susceptible C57BL/6 
mice and EAMG nonsusceptible SWR and SJL/J mice, 
were injected with AChR and examined for antibody 
titers, for EAMG and for AChR a-subunit mRNA. 
AChR-immunized mice of all strains developed com- 
parable titers of anti-AChR antibodies (Fig. 1B). Of all 
Probe: CY p Y E s Cl-Actin 
AChR-immunized mice, an increase in AChR (Y- 
subunit mRNA was observed only in C57BL/6 mice 
which displayed symptoms of EAMG (Fig. 3). Based 
on the densitometric evaluation of autoradiograms this 
increase was 9.1 + 1.4-fold, as compared to control, 
CFA-immunized mice, and calculated for three dif- 
ferent experiments. AChR-immunized SWR mice 
(Fig. 3) and SJL/J mice (data not shown) did not 
display any increase in their AChR a-subunit mRNA. 
It should be noted that C57BL/6 mice which had been 
immunized with Torpedo AChR, without developing 
any myasthenic symptoms had no elevated a-subunit 
mRNA. In accordance with the results in rabbits and 
mice, increased AChR a-subunit mRNA levels cor- 
related with disease also in rats. Thus, only sick animals 
exhibited increased levels of AChR a-subunit mRNA, 
whereas in AChR-immunized rats, which did not show 
any of the clinical symptoms of EAMG, there was no 
such increase (Fig. 4). The overall anti-AChR antibody 
titers of sick and healthy AChR-injected rats were 
similar (Fig. 1C). 
In order to find out whether the observed increase in 
a-subunit mRNA in myasthenic rats is also seen for the 
other receptor subunits, the poly(A)+ RNA samples 
were hybridized with specific probes for the &, y-, 6- 
and e-subunits. As shown in Fig. 4, in addition to the 
increase in a-subunit mRNA, an increase in the specific 
transcripts for the ,~3,6 and 6 was observed. The mRNA 
for the y-subunit was undetectable in control as well as 
in myasthenic rats. The y-subunit probe employed gave 
a positive signal when hybridized with RNA from rat 
primary muscle cell cultures (data not shown). The 
relative increase in the level of (Y-, ,&, f- and J-subunit 
mRNA was calculated to be 5.2-, 1.6-, 3.2- and 
3.7-fold, respectively. No significant changes in the 
level of mRNA transcripts for all AChR subunits were 
detected in AChR-injected rats which did not exhibit 
myasthenic symptoms. A decrease in AChR content in 
myasthenic rats was observed, as has been reported 
previously [ 181. The loss of membranal AChR content 
was 52% in myasthenic rats and only 27% in AChR- 
immunized rats which did not display EAMG. 
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Fig. 4. Northern blot analysis of transcripts of AChR subunits in rat muscles. Poly(A)+ RNA (10 fig) from hind leg muscle were analyzed by 
blot hybridization using AChR (Y-, ,&, y-, e- and &DNA probes, and cY-actin-specific DNA probe. For each probe, RNA from control CFA- 
injected (lane l), nonmyasthenic AChR-injected (lane 2) and myasthenic AChR-injected (lane 3) rats was analyzed as described in Fig. 2. 
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4. DISCUSSION 
In this report we have shown that an increase in 
AChR transcripts correlates exclusively with the expres- 
sion of EAMG. Only animals which exhibit myasthenic 
symptoms display increased levels of AChR-mRNA. 
On the other hand, animals with high anti-AChR an- 
tibody titers which do not have myasthenia, such as 
rabbits immunized with RCM-AChR or AChR- 
immunized rats and mice that were not sick, did not 
have increased levels of AChR transcripts. It is possible 
that only a distinct population of antibodies which 
damage the neuromuscular junction and interfere with 
proper muscle activity can result in altered regulation 
of gene expression. 
It has been reported that the levels of surface mem- 
brane AChR are reduced in EAMG [18,19]. We have 
also observed a reduction in membranal AChR content 
in myasthenic rabbits and rats (46% and 52%, respec- 
tively) along with an increase in AChR gene expression. 
These reduced levels of AChR content may represent 
an essentially higher loss in AChR, which is partially 
compensated by elevated amounts of newly synthesized 
AChR, resulting from the increase in AChR 
transcripts. It should be noted that some decrease in 
AChR content was also detected in RCM-AChR-in- 
jetted rabbits (21%) and in nonmyasthenic AChR- 
injected rats (27%). These nonmyasthenic animals did 
not display increased AChR-mRNA levels. Possibly, 
the increase in AChR transcripts is triggered only above 
a certain threshold loss in AChR content, which is also 
accompanied by damage to the neuromuscular 
junction. 
Messenger RNA levels for the AChR subunits were 
shown to be regulated by denervation, embryonic 
development and muscle activity. Denervation resulted 
in an increase of AChR transcripts [20-241. Specifical- 
ly, an increase in the levels of mRNA coding for the (Y-, 
,&, y- and a-subunits of AChR was observed following 
denervation, whereas only a small increase in the 
mRNA coding for the f-subunit was observed [4]. 
Thus, denervation results mainly in an increased level 
of AChR transcripts corresponding to the embryonic 
(cu2ays) receptor, accompanied by the elevation of the 
respective extrajunctional AChR. In our study on 
myasthenic rats we observed an increase in the level of 
the c-subunit mRNA (3.2-fold) whereas the y-subunit 
transcripts remained undetectable. The increase in the 
c-subunit mRNA is relatively similar to the increase of 
the LY-, f3- and B-subunit mRNA (5.2-, 1.6- and 3.7-fold, 
respectively). In agreement with previous reports on 
denervation [24] we have also observed that the amount 
of &subunit transcript in control animals was high 
relative to the other subunit transcripts (Fig. 4), and in- 
creased less than the (Y-, c- and b-transcripts in EAMG. 
It appears from our experiments that EAMG is ac- 
companied by a moderate increase in the level of AChR 
234 
transcripts which corresponds to the adult, junctional 
receptor (q&J). It is thus reasonable to anticipate that 
if more AChR transcripts are being made as a compen- 
satory mechanism, they will be of the type which is be- 
ing lost and needed, i.e. the adult form. We do not 
know yet whether the observed increased AChR mRNA 
levels in EAMG result in an increase in newly synthesiz- 
ed adult AChR, and whether this newly synthesized 
AChR is properly inserted into the end plate. In this 
respect it should be mentioned that earlier studies by 
Cull-Candy et al. [25] demonstrated that the properties 
of the end plate channels (single channel conductance 
and mean channel-life time) in myasthenia gravis are 
identical to the properties of the channel in normal 
muscle. This may support the notion that the newly 
made junctional AChR in EAMG is of the adult form 
(i.e. K&J). 
In conclusion, we have shown that regulation of 
AChR gene expression is modulated in EAMG and 
might be important for elucidating the mechanism and 
control of myasthenia. This regulation seems to be dif- 
ferent from that observed in denervation and provides 
a different physiological condition for resolving the 
diverse mechanisms controlling muscle AChRs. 
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